Haleon (ADR) (HLN)
Sells everyday-health brands assembled from the consumer portfolios of GSK, Novartis and Pfizer.
$9.29
After hours+0.04 (+0.49%)
At close$9.25(−1.23%)
In millions of USD, except per-share figures · converted from GBP at the latest rate
| In millions | Q2 FY22Jun 2022 | Q4 FY22Dec 2022 | Q2 FY23Jun 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q4 FY25Dec 2025 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3,506 | 3,859 | 7,658 | 7,425 | 3,896 | 7,599 | 3,710 | 7,392 | 3,657 | 7,313 | 7,361 | 7,531 |
| Cost of revenue | 1,353 | 1,432 | 2,920 | 3,159 | 1,443 | 2,749 | 1,377 | 2,855 | 1,298 | 2,596 | 2,574 | 2,557 |
| Gross profit | 2,153 | 2,428 | 4,738 | 4,267 | 2,453 | 4,850 | 2,333 | 4,537 | 2,359 | 4,718 | 4,787 | 4,974 |
| 1,531 | 1,668 | 3,215 | 3,126 | 1,579 | 3,304 | 1,392 | 3,130 | 1,556 | 3,112 | 3,118 | 3,178 | |
| Research & development | 85 | 109 | 190 | 226 | 95 | 192 | 101 | 206 | 102 | 204 | 216 | 198 |
| 1,449 | 1,596 | 3,019 | 2,665 | 1,475 | 2,928 | 1,456 | 2,773 | 1,445 | 2,891 | 2,902 | 2,981 | |
| Selling & marketing | 0 | 0 | 0 | 2,700 | 0 | −81 | 0 | −159 | 0 | 0 | 0 | 0 |
| General & administrative | 1,449 | 1,596 | 3,019 | −35 | 1,475 | 3,009 | 1,456 | 2,932 | 0 | 0 | 0 | 0 |
| Other expenses | −4 | −37 | 4 | 236 | 9 | 184 | −165 | 151 | 9 | 17 | 0 | 0 |
| Operating income | 622 | 759 | 1,523 | 1,141 | 874 | 1,536 | 941 | 1,408 | 803 | 1,605 | 1,669 | 1,796 |
| −1 | −99 | −242 | −250 | −87 | −207 | −105 | −188 | −85 | −171 | −240 | −376 | |
| Interest income | 9 | 9 | 51 | 3 | 29 | 41 | 16 | 81 | 0 | 0 | 41 | 46 |
| Interest expense | 11 | 108 | 292 | 295 | 129 | 258 | 120 | 268 | 86 | 172 | 218 | 206 |
| Other non-operating income | −9 | −9 | −51 | −524 | −43 | 80 | −15 | −99 | −9 | −19 | 0 | 0 |
| Income before tax | 621 | 661 | 1,281 | 891 | 787 | 1,329 | 835 | 1,220 | 717 | 1,435 | 1,428 | 1,420 |
| Income tax expense | 144 | 173 | 307 | 383 | 199 | 323 | 169 | 258 | 175 | 350 | 279 | 384 |
| Net income from continuing operations | 476 | 487 | 974 | 508 | 589 | 1,006 | 666 | 962 | 542 | 1,085 | 1,150 | 1,035 |
| Net income | 458 | 460 | 917 | 483 | 565 | 969 | 647 | 956 | 538 | 1,076 | 1,142 | 1,024 |
| EPS, basic | $0.10 | $0.10 | $0.20 | $0.10 | $0.12 | $0.21 | $0.15 | $0.21 | $0.12 | $0.24 | $0.25 | $0.23 |
| EPS, diluted | $0.10 | $0.10 | $0.20 | $0.10 | $0.12 | $0.21 | $0.15 | $0.21 | $0.12 | $0.24 | $0.25 | $0.23 |
| Weighted average shares, basic | 4,617 | 4,617 | 4,603 | 4,624 | 4,598 | 4,589 | 4,562 | 4,608 | 4,528 | 4,528 | 4,450 | 4,443 |
| Weighted average shares, diluted | 4,617 | 4,617 | 4,631 | 4,624 | 4,598 | 4,606 | 4,562 | 4,608 | 4,532 | 4,532 | 4,481 | 4,460 |
| EBITDA | 691 | 828 | 1,737 | 1,791 | 917 | 2,006 | 956 | 1,687 | 890 | 1,859 | 1,913 | 2,022 |
| Depreciation & amortization | 60 | 60 | 163 | 125 | 64 | 276 | 64 | 129 | 78 | 235 | 244 | 226 |
| EBIT | 631 | 769 | 1,573 | 1,666 | 917 | 1,456 | 956 | 1,557 | 812 | 1,624 | 1,669 | 1,796 |